The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial

1. Amsterdam UMC, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; 2. Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, the Netherlands; 3. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 4. Department of Cardiology, Tergooi Hospital, Blaricum, the Netherlands; 5. Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands

We conducted the AIDA trial comparing the Absorb™ bioresorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara, CA, USA) with the XIENCE everolimus-eluting stent (EES; Abbott Vascular) in daily practice to assess the complete safety and efficacy of the Absorb throughout the scaffold bioresorption period. Preclinical studies have shown that scaffold bioresorption takes 36 months1. Clinical studies have demonstrated that this period of scaffold bioresorption is associated with higher rates of device thrombosis2. Therefore, we herein report the complete three-year clinical outcomes of the Absorb in comparison with the XIENCE.


The study design, study population and ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article

The AFR-PRELIEVE TRIAL A prospective, non-randomized, pilot study to assess the Atrial Flow Regulator (AFR) in Heart Failure Patients with either preserved or reduced ejection fraction